David Floch

Pharmacokinetics, pharmacodynamics and safety of <scp>QGE</scp>031 (ligelizumab), a novel high‐affinity anti‐IgE antibody, in atopic subjects

Jonathan Arnold A. P., I. Bottoli, Andrej Skerjanec et al. · Clinical & Experimental Allergy · 2014 · 239 citations · Full text

Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study

Benjamin A. Fisher, Antónia Szántó, Wan‐Fai Ng et al. · The Lancet Rheumatology · 2020 · 113 citations

Rheumatoid Disorder, Rheumatology, Autoimmune Disease +14

Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis

Haiying Sun, Linh Van, David Floch et al. · The Journal of Clinical Pharmacology · 2016 · 43 citations

Immunodeficiencies, Immunology, Inflammatory Arthritis +21

Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis

Abhijit Chakraborty, Linh Van, Andrej Skerjanec et al. · The Journal of Clinical Pharmacology · 2013 · 34 citations

Total Serum Il-1β, Immunology, Pharmacotherapy +21

Novel Anti-CD40 Monoclonal Antibody CFZ533 in Patients with Primary Sjogren Syndrome: A Phase Iia Double-Blind, Placebo–Controlled Randomized Trial

Arwa M. Farag, Athena Papas, Benjamin A. Fisher et al. · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · 2018 · 14 citations

Clinical Immunology, Rheumatology, Autoimmune Disease +13